Sonnet BioTherapeutics Holdings, Inc. reported earnings results for the full year ended September 30, 2023. For the full year, the company reported net loss was USD 18.83 million compared to USD 29.72 million a year ago. Basic loss per share from continuing operations was USD 18.14 compared to USD 150.52 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.7 USD | -6.10% | -8.62% | -2.30% |
Mar. 11 | Traders Anticipate Inflation Report as US Equities Open Lower on Wall Street | MT |
Mar. 11 | Top Premarket Gainers | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-2.30% | 5.22M | |
+30.38% | 684B | |
+26.51% | 568B | |
-4.36% | 361B | |
+19.30% | 329B | |
+3.73% | 284B | |
+16.70% | 240B | |
+8.78% | 208B | |
-7.93% | 200B | |
+7.68% | 166B |
- Stock Market
- Equities
- SONN Stock
- News Sonnet BioTherapeutics Holdings, Inc.
- Sonnet BioTherapeutics Holdings, Inc. Reports Earnings Results for the Full Year Ended September 30, 2023